EUVIMEDEUVIMED entdecken
Open Access

Maternal periconception hyperglycemia, preconception diabetes, and risk of major congenital malformations in offspring

Ran S Rotem iD, Marc G Weisskopf iD, Brian Bateman, Krista Huybrechts iD, Sonia Hernández-Diáz

Human Reproduction · 2024

DOI: 10.1093/humrep/deae233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, 2024. Verfasst von Ran S Rotem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Hauptthemen laut MEDLINE: Glycated Hemoglobin, Congenital Abnormalities, Hyperglycemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NICHD NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY QUESTION What are the roles of maternal preconception diabetes and related periconceptional hyperglycemia on the risk of major congenital malformations (MCMs) in offspring? SUMMARY ANSWER Maternal periconceptional glycated hemoglobin (HbA1c) levels over 5.6% were associated with an increased risk of congenital heart defects (CHD) in the offspring, and maternal preconception diabetes was associated with an increased risk of CHD, including when HbA1c levels were within euglycemic ranges. WHAT IS KNOWN ALREADY Maternal preconception diabetes has been linked with MCMs in the offspring. However, evidence concerning associations with specific periconception serum measures of hyperglycemia, and susceptibility of different organ systems, is inconsistent. Moreover, limited evidence exists concerning the effectiveness of antidiabetic medications in mitigating diabetes-related teratogenic risks. STUDY DESIGN, SIZE, DURATION A large Israeli birth cohort of 46 534 children born in 2001–2020. PARTICIPANTS/MATERIALS, SETTING, METHODS Maternal HbA1c test results were obtained from 90 days before conception to mid-pregnancy. Maternal diabetes, other cardiometabolic conditions, and MCMs in newborns were ascertained based on clinical diagnoses, medication dispensing records, and laboratory test results using previously validated algorithms. Associations were modeled using generalized additive logistic regression models with thin plate penalized splines. MAIN RESULTS AND THE ROLE OF CHANCE Maternal periconceptional HbA1c value was associated with CHD in newborns, with the risk starting to increase at HbA1c values exceeding 5.6%. The association between HbA1c and CHD was stronger among mothers with type 2 diabetes mellitus (T2DM) compared to the other diabetes groups. Maternal pre-existing T2DM was associated with CHD even after accounting for HbA1C levels and other cardiometabolic comorbidities (odds ratio (OR)=1.89, 95% CI 1.18, 3.03); and the OR was materially unchanged when only mothers with pre-existing T2DM who had high adherence to antidiabetic medications and normal HbA1c levels were considered. LIMITATIONS, REASONS FOR CAUTION The rarity of some specific malformation groups limited the ability to conduct more granular analyses. The use of HbA1c as a time-aggregated measure of glycemic control may miss transient glycemic dysregulation that could be clinically meaningful for teratogenic risks. WIDER IMPLICATIONS OF THE FINDINGS The observed association between pre-existing diabetes and the risk of malformations within HbA1c levels suggests underlying causal pathways that are partly independent of maternal glucose control. Therefore, treatments for hyperglycemia might not completely mitigate the teratogenic risk associated with maternal preconception diabetes. STUDY FUNDING/COMPETING INTEREST(S) The work was supported by NIH grants K99ES035433, R01HD097778, and P30ES000002. None of the authors reports competing interests. TRIAL REGISTRATION NUMBER N/A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycated HemoglobinCongenital AbnormalitiesHyperglycemiaHumansFemalePregnancyAdultInfant, NewbornPregnancy in DiabeticsHeart Defects, CongenitalIsraelRisk FactorsPrenatal Exposure Delayed EffectsMaleDiabetes Mellitus, Type 2Cohort StudiesHypoglycemic Agents

Stichwörter der Autor:innen

HbA1ccongenital anomaliesdiabeteshyperglycemiateratogenicity

Substanzen

Glycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Ran S Rotem, Marc G Weisskopf, Krista Huybrechts

Förderung

  • NIEHS NIH HHS
  • NICHD NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Rotem, R. S., Weisskopf, M. G., Bateman, B., Huybrechts, K., & Hernández-Diáz, S. (2024). Maternal periconception hyperglycemia, preconception diabetes, and risk of major congenital malformations in offspring. Human Reproduction. https://doi.org/10.1093/humrep/deae233

Vancouver

Rotem RS, Weisskopf MG, Bateman B, Huybrechts K, Hernández-Diáz S. Maternal periconception hyperglycemia, preconception diabetes, and risk of major congenital malformations in offspring. Human Reproduction. 2024. doi:10.1093/humrep/deae233

BibTeX
@article{Rotem2024,
  author = {Rotem, Ran S and Weisskopf, Marc G and Bateman, Brian and Huybrechts, Krista and Hernández-Diáz, Sonia},
  title = {Maternal periconception hyperglycemia, preconception diabetes, and risk of major congenital malformations in offspring},
  journal = {Human Reproduction},
  year = {2024},
  doi = {10.1093/humrep/deae233}
}
Kostenlos starten →